MVP (major vault protein) by Viguié, F









Atlas Genet Cytogenet Oncol Haematol. 2000; 4(2)  
 
68 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
MVP (major vault protein) 
Franck Viguié 
Laboratoire de Cytogénétique - Service d'Hématologie Biologique, Hôpital Hôtel-Dieu, 75181 Paris Cedex 
04, France (FV) 
 
Published in Atlas Database: May 2000 
Online updated version : http://AtlasGeneticsOncology.org/Genes/LRPID120.html 
DOI: 10.4267/2042/37616 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2000 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Other names: LRP (lung resistance-related protein) 
HGNC (Hugo): MVP 
Location: 16p11.2 
Note: Drug resistance gene, codes for a "lung 
resistance-related protein" (LRP) originally detected in 
a lung carcinoma cell line resistant to chemotherapy. 
DNA/RNA 
Transcription 




110 kD protein, 896 amino acids; major cytoplasmic 
vault protein; vaults are nucleoproteic complexes 
composed of the MVP associated with two high-
molecular weight proteins p240 and p193 which 
surround a small 140 nucleotides RNA species. 
Expression 
Expressed in a variety of human tumor cell lines, the
major part being multidrug resistant; expressed also in 
primary solid tumors, mainly colon carcinoma or 
ovarian carcinoma, as well as in hematopoietic cancers 
(myelodysplastic syndrome, acute myeloid or lymphoid 
leukemia, multiple myeloma); in normal tissues, LRP 
expression has a wide distribution, with particularly 
high levels in epithelial cells of the digestive tract. 
Localisation 
Cytoplasmic, in the cytosol, with a little fraction 
(approximately 5%) located in the nuclear membrane 
and nuclear pores. 
Function 
Vault are cytoplasmic organelles which mediate 
bidirectional nucleocytoplasmic transport of a wide 
range of substrates, including cytotoxic drugs; vaults 
would be involved both in vesicule and cytosolic 
transport of molecules. 
Homology 
104 kD rat MVP. 
Implicated in 
Implicated in induced multidrug-resistance to 
anticancer chemotherapy 
Disease 
It includes resistance to doxorubicin, vinca alkaloids, 
mitoxantrone and etoposide; the role of LRP by itself in 
multidrug-resistance is not completely clear because it 
is only a part of a nucleo-proteic complex involved in 
macromolecules transport; the introduction and 
expression of the LRP gene in cells by transfection 
does not confer a multidrug-resistance phenotype; 
overexpression of LRP has been associated with poor
response to chemotherapy in various types of leukemia 
and in ovarian carcinoma, however the role of LRP as 
pronostic factor remains controversial; in multi-
resistant cell lines, LRP amplification within a 
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